Last reviewed · How we verify
Chong Kun Dang Tofacitinib Tablet
At a glance
| Generic name | Chong Kun Dang Tofacitinib Tablet |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chong Kun Dang Tofacitinib Tablet CI brief — competitive landscape report
- Chong Kun Dang Tofacitinib Tablet updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI